FINGENIOUS®

Ikkuna Suomen biopankkiaineistoon ja biolääketieteelliseen tutkimukseen

Sosiaalilääketieteen syysseminaari 19.11.2020

Biopankkien Osuuskunta Suomi –FINBB Laura Mustaniemi, FM, KTM, Asiakkuus- ja palvelujohtaja Mirkka Koivusalo, FT, Tiede- ja viestintäpäällikkö





Improving R&D Productivity

Accelerated drug discovery and development



Shorter timespan from concept to discovery by Finnish biobanks services



- Millions of samples available from all hospital biobanks through one service
- Clinical data
- Pre-pooled study participants based on biobank consents
- Recontacting of patients
- University Hospitals' clinicians and their expertise



Why Finland?

- Biobank Act since 2013
- Act on Secondary Use of Health and Social Care Data since 2020
- 100% penetration of electronic health records (EHR)
- Unique personal ID codes
- Population based high quality public health care

- All Finnish public biobanks accessible through one service, Fingenious®
- Over 11 million samples
- Nearly 500,000 samples genotyped
- Possibility for recontacting patients



Finnish Biobank Cooperative -FINBB

- Our founding partners are six biggest Hospital Districts, six Universities and Finnish Institute for Health and Welfare (THL)
- FINBB offers a one-access-shop for easy access to Finnish biobank materials, biodata and study participants

- We serve researchers from both academia and industry
- We co-create services and products with our customers and founding partners
- We give value back to hospitals and universities in Finland

Partnership and Collaboration



FOUNDING UNIVERSITIES

FOUNDING HOSPITALS FINNISH HOSPITAL DISTRICTS

STRATEGIC BIOBANKS COLLABORATION

























BICPANKK





























- Patient, data and sample finding
- Study set-up and single point of contact
- Data and sample delivery and analytics

Researchers



FINGENIOUS®

Your Digital Gateway to Finnish Biobanks and Biomedical Research



What is Fingenious®?

A digital gateway to Finnish biobanks and biomedical research – the 1st in class service in Europe



Built to serve academic and industry researchers and to advance medical research globally



A single point of contact for all public biobanks and their samples and data.

One contract with all the biobanks via FINBB.





FinnGen - Great Performance by Finnish Biobanks



HELSINGIN BIOPANKKI HELSINGFORS BIOBANK

Finnish Clinical



Biobank

















U NOVARTIS

















During FinnGen1 (3 years), the number of new consented samples in Finnish biobanks increased 30,000 → 253,000














At the end of Aug 2020:

- 158,500 legacy samples
- 253,000 new samples
- Total of **411,500** available samples




Biobank Studies in Finnish Biobanks





A broad pipeline is emerging across neuromuscular diseases across all phases with a concentration in ALS and DMD

Exhibit 25: Neuromuscular Disease Pipeline by Phase and Type of Therapy




Source: Understanding Neuromuscular Disease Care: Current State and Future Prospects, IQVIA Institute for Human Data Science, Oct 2018



Main Neuromuscular Diseases in Finnish Biobanks

Patients with neuromuscular disorders with GWAS analyzed samples (FinnGen DF6)





FINGENIOUS®

How to Access Samples and Data





FINBB Works Together with Biobanks for Fingenious®

Finnish Hospital Richanks

- 106 employees
- Roles:
 - administration
 - project management
 - research management
 - laboratory staff
 - sample teams
 - process teams
 - customer services teams
 - biobank pathologists
 - IT


Expertise in:

- modern biobanking
- bioanalytics
- real-world data
- research
- sample collection and storage
- sample processing and sectioning
- sample digitalization
- H&E staining
- tissue microarrays

- TMA construction
- DNA/RNA extraction
- PBMC processing
- disease model pathology
- data management
- data analytics
- Al
- ICT
- legal aspects



Continuously Enriching Base Data: FINBB's Services Strengthened by FinnGen





Data Enrichment: A Practical

Example



Over 11 million samples




Example:
Neuromuscular
diseases, GWAS
analyzed samples



Available via Fingenious®

- Includes FFPE samples
- The majority of samples are legacy samples
- New samples coming in continuosly



- FinnGen data returned to biobanks every six months
- Data returned from other biobank studies
- Available together with samples, clinical and other longitudinal health record data



Three Steps Designed to Serve Researchers

1. Fingenious® Catalogue

2. Fingenious® Feasibility

3. Fingenious® Access



ICD-10 Catalogue



Feasibility request



Access request



Further development ongoing


Sketch your study faster

Plan your study smarter with less effort and wide outreach

Start your study with less paperwork




Step 1






Step 2












Fingenious® and Your Research Needs



Choose your desired combination of data and service



Take home messages

- Access to unique Finnish biobank data
- FinnGen creates new international research opportunities
- Registration at fingenious.fi

